Clinical trials: Fat; Liver
Non-Alcoholic Fatty Liver Disease
Safety and Efficacy of Hoodia Gordonii for Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
This clinical study is designed to evaluate the safety of oral administration of the medical food Hoodia to patients with non alcoholic fatty liver disease.
- Trial name
- NCT00816465
- Testing
- Hoodia gordonii
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Total Pancreatectomy, Pancreaticoduodenectomy
Hepatic Histology and Metabolism Following Total Pancreatectomy and Pancreaticoduodenectomy
The objective of the study is to investigate the development of NAFLD following total pancreatectomy and pancreaticoduodenectomy and to explore the histological and metabolic changes following the procedures.
- Conditions
- Total Pancreatectomy, Pancreaticoduodenectomy, Pancreatic Diabetes, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03864744
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- Steno Diabetes Center Copenhagen
Nash
Psoriasis and Non Alcoholic Steatohepatitis: Is There a Shared Inflammatory Network ?
The study is to assess frequency of NASH in Psoriatic patient and to measure the level of proinflammatory cytokines including TNFα, interleukin (IL)-6 and IL-17 and anti-inflammatory cytokines including IL10, IL35 by ELISA.
- Trial name
- PANASH (NCT05994677)
- Volunteers
- 59 people
- Sponsor
- Assiut University
Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.
- Conditions
- Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis
- Trial name
- TESA-LIVER (NCT07481734)
- Testing
- Tesamorelin, Standardized lifestyle counseling
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hudson Biotech
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
Type 2 Diabetes, NAFLD
Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus
Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although…
- Conditions
- Type 2 Diabetes, NAFLD, Obesity, Dyslipoproteinaemia
- Trial name
- DiNA-D (NCT02459496)
- Testing
- dietary consulting and advise
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Institute of Human Nutrition
Non-alcoholic Steatohepatitis
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
- Trial name
- NCT02912260
- Testing
- MGL-3196
- Where
- 26 sites in United States
- Volunteers
- 125 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
NASH
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Part 1: This is a multi-center evaluation of pegozafermin (administered weekly or every other week) in a randomized, double-blind, placebo-controlled study administered for 12 weeks in participants with NASH and NAFLD at high…
- Trial name
- NCT04048135
- Testing
- Pegozafermin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- 89bio, Inc.
Nonalcoholic Steatohepatitis
Dose Escalation Study of Kylo-0603 in Healthy Subjects
This clinical trial is the first-in-human study of Kylo-0603. The purpose of this randomized, double-blind, placebo-controlled phase 1 study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and effect of…
- Trial name
- NCT06365580
- Testing
- Kylo-0603 capsule
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Kylonova (Xiamen) Biopharma co., LTD.
NAFLD, Obesity
Intermittent Fasting, Mediterranean Diet and NAFLD
This study aims to evaluate the effects of Intermittent Fasting (IF) 14/10 compared with the Low Glycemic Index Mediterranean Diet on NAFLD.
- Conditions
- NAFLD, Obesity, Intermittent Fasting, Mediterranean Diet
- Trial name
- RC2024-21 (NCT06615817)
- Testing
- Intermittent Fasting
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Fatty Liver
NAFLD: Independent Effects of Western Dietary Pattern Profile and Sedentary Life
Investigators perform a counseling intervention study (6 months) in adult subjects with evidence of Fatty Liver by Ultrasound, graded 0-3 according to the Bright Liver Score (BLS); exclusion criteria are diabetes, renal…
- Trial name
- ct-NAFLD (NCT02670590)
- Testing
- diet
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele
Non-alcoholic Fatty Liver Disease
Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in…
- Trial name
- LIGHT-ON (NCT02147925)
- Testing
- Liraglutide combined with metformin, Insulin glargine combined with metformin, Sitagliptin combined with metformin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Type 2 Diabetes
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty liver disease (NAFLD) has not been systematically studied before, and in particular, never when using the new insulin formulations detemir…
- Trial name
- NCT00998335
- Testing
- Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.
The primary objective of this study is to assess the clinical performance of LIVERFAStTM In Vitro Diagnostic (IVD) Tests (Fibrosis score, Activity score and Steatosis score) in NAFLD suspected patients for staging of fibrosis and…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04579874
- Testing
- LIVERFASt
- Where
- 8 sites in United States
- Volunteers
- 241 people
- Sponsor
- Fibronostics USA, Inc
Type 2 Diabetes, NAFLD
Nutraceutical Improvement of Glucose Metabolism, NAFLD and Insulin Resistance by Oat-fiber Supplementation in Type 2 Diabetes Mellitus Patients
Cohort studies show an association between increased intake of insoluble (cereal) fiber and decreased risk for cardiovascular disease, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cancer, infectious and…
- Trial name
- NIMROD (NCT05654805)
- Testing
- Drinking powder supplement
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- Charite University, Berlin, Germany
Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease
Healthy Liver - Healthy Brain
People with liver disease report difficulties with attention and problem-solving skills. Diet plays an important role in the development of liver disease and/or pre-diabetes.
- Conditions
- Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, NAFLD, Pre-diabetes
- Trial name
- NCT05216796
- Testing
- Diet Intervention
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Non-Alcoholic Fatty Liver Disease
Hydrogen-rich Water for Non-alchoholic Fatty Liver Disease
This study evaluates how 4-week supplementation with hydrogen-rich water affects liver fat accumulation, blood lipid profiles and body composition in patients with non-alcoholic fatty liver disease
- Trial name
- NCT03625362
- Testing
- Hydrogen
- Where
- 2 sites in Serbia
- Volunteers
- 10 people
- Sponsor
- University of Novi Sad, Faculty of Sport and Physical Education
Steatohepatitis, Nonalcoholic, Nonalcoholic Fatty Liver
Digital Therapy for Fatty Liver Disease
This study is a randomised controlled trial of the clinical application of the Fatty Liver Data Analysis and Intervention System (FLDAS) to compare the effectiveness of traditional lifestyle interventions in patients with fatty…
- Trial name
- DTFLD (NCT07007741)
- Testing
- Software Group
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Non-alcoholic Steatohepatitis
Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of single and multiple doses of ARO-HSD in healthy adult volunteers and in patients with NASH or suspected NASH.
- Trial name
- NCT04202354
- Testing
- ARO-HSD Injection, sterile normal saline (0.9% NaCl)
- Where
- New Zealand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals